A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Clinical trial NCT06384261 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06384261
- Sponsor
- OncoVerity, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-22
- Primary completion
- 2027-01-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.